ATE400814T1 - Pin1 als stadiumsmarker der aggressivität und/oder der metastasierung abnormale zellwachstum - Google Patents

Pin1 als stadiumsmarker der aggressivität und/oder der metastasierung abnormale zellwachstum

Info

Publication number
ATE400814T1
ATE400814T1 AT00982293T AT00982293T ATE400814T1 AT E400814 T1 ATE400814 T1 AT E400814T1 AT 00982293 T AT00982293 T AT 00982293T AT 00982293 T AT00982293 T AT 00982293T AT E400814 T1 ATE400814 T1 AT E400814T1
Authority
AT
Austria
Prior art keywords
pin1
cell growth
abnormal cell
metastasization
aggressivity
Prior art date
Application number
AT00982293T
Other languages
English (en)
Inventor
Kun Lu
Gerburg Wulf
Xiao Zhou
Original Assignee
Beth Israel Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Hospital filed Critical Beth Israel Hospital
Application granted granted Critical
Publication of ATE400814T1 publication Critical patent/ATE400814T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/99—Isomerases (5.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT00982293T 1999-11-29 2000-11-29 Pin1 als stadiumsmarker der aggressivität und/oder der metastasierung abnormale zellwachstum ATE400814T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16780099P 1999-11-29 1999-11-29
US25367600P 2000-11-28 2000-11-28

Publications (1)

Publication Number Publication Date
ATE400814T1 true ATE400814T1 (de) 2008-07-15

Family

ID=26863487

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00982293T ATE400814T1 (de) 1999-11-29 2000-11-29 Pin1 als stadiumsmarker der aggressivität und/oder der metastasierung abnormale zellwachstum

Country Status (7)

Country Link
EP (1) EP1234185B1 (de)
JP (1) JP2003515172A (de)
AT (1) ATE400814T1 (de)
CA (1) CA2392917C (de)
DE (1) DE60039453D1 (de)
HK (1) HK1051066A1 (de)
WO (1) WO2001038878A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2437784A1 (en) 2001-02-09 2002-08-22 Pintex Pharmaceuticals, Inc. Pin1 as a marker for prostate cancer
JP2004533603A (ja) * 2001-02-09 2004-11-04 ピンテックス ファーマシューティカルズ，インク． 異常な細胞成長に関するマーカとしてのｐｉｎ１
ATE550662T1 (de) 2001-09-12 2012-04-15 Inst Medical W & E Hall Diagnose- und behandlungsverfahren sowie dafür geeignete mittel
DE60200248T2 (de) 2002-08-01 2005-01-27 Mtm Laboratories Ag Verfahren für Lösung-basierte Diagnose
AU2003290988A1 (en) 2002-11-14 2004-06-15 Pintex Pharmaceuticals, Inc. Levels of pin1 in normal and cancerous tissue
WO2022032179A1 (en) * 2020-08-07 2022-02-10 The Regents Of The University Of California Pin1 inhibitors and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972697A (en) * 1995-11-13 1999-10-26 The Salk Institute For Biological Studies NIMA interacting proteins
US6495376B1 (en) * 1999-02-18 2002-12-17 Beth Israel Deaconess Medical Center Methods and compositions for regulating protein-protein interactions

Also Published As

Publication number Publication date
WO2001038878A3 (en) 2002-01-17
CA2392917C (en) 2007-05-01
DE60039453D1 (de) 2008-08-21
JP2003515172A (ja) 2003-04-22
EP1234185B1 (de) 2008-07-09
CA2392917A1 (en) 2001-05-31
EP1234185A2 (de) 2002-08-28
WO2001038878A2 (en) 2001-05-31
HK1051066A1 (zh) 2003-07-18

Similar Documents

Publication Publication Date Title
WO2002065091A3 (en) Pin1 as marker for abnormal cell growth
ATE449869T1 (de) Verfahren zur beurteilung der wirksamkeit von chemotherapeutika
EA200501772A1 (ru) Способы измерения экспрессии генов из фиксированного и залитого в парафин образца ткани
WO2003009814A3 (en) Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
WO2005032343A3 (en) Hedgehog signaling in prostate regeneration neoplasia and metastasis
WO2004083816A3 (en) Loss of heterozygosity of the dna markers in the 12q22-23 region
WO2005005601A3 (en) Compositions and methods for treating and diagnosing cancer
DE69900841D1 (de) Durch enzymkatalyse erhaltene therapeutische substanzen.
ATE389008T1 (de) Verfahren und vorrichtung zum züchten und/oder behandeln von zellen
EP1604203A4 (de) Verfahren zum direkten nachweis einzelner methotrexatmetabolite
WO2003048300A3 (en) Methods of identifying cellular target molecules
WO2004106495A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2006028655A3 (en) Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
CY1108540T1 (el) Ταυτοποιηση θεραπευτικων ενωσεων
AU2003302732A1 (en) Method for identifying risk of breast cancer and treatments thereof
ATE463092T1 (de) Busmodem für gebäude- und industrielle elektrische systeme
ATE400814T1 (de) Pin1 als stadiumsmarker der aggressivität und/oder der metastasierung abnormale zellwachstum
DE60044350D1 (de) Prostata-spezifisches gen pcgem1 und methoden zu dessen verwendung zur erkennung, behandlung und prävention von prostatakrebs
WO2004005530A3 (en) Compositions and methods for treatment and detection of multiple cancers
WO2003030725A3 (en) Pancreatic cancer diagnosis and therapies
DE60036551D1 (de) VERWENDUNG VON BAKTERIELLEN ParD kis/ParD kid TOXIN-ANTITOXIN SYSTEM ZUR TÖTUNG VON EUKARYOTISCHEN ZELLEN
MXPA05001690A (es) Estrategia de deteccion para farmacos anticancer.
WO2007081790A3 (en) Methods for diagnosing and treating prostate cancer
WO2006052735A3 (en) Fibulin-3 and uses thereof
WO2002044417A3 (en) Expression analysis of inhibitor of differentiation nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties